API China, the first and longest-running pharmaceutical ingredients exhibition in China brought in over 30,000 visitors and around 1,200 exhibitors between 12 and 14 November 2025 at 70,000 square meters of exhibition space at Chongqing International Expo Center.
Enriching its visitors and spectators for four decades, the show still remains a landmark in the pharmaceutical ecosystem of China, underscoring major industry themes that include the likes of manufacturing efficiency, therapeutic and formulation innovation, quality and regulatory excellence, sustainable development, biopharma as well as digitalization throughout the pharmaceutical value chain.
Excellence and Industry Leadership – Bringing a Legacy
A very strong participation went on to highlight sustained confidence in the evolving pharmaceutical landscape that China holds. Exhibitors as well as buyers went on to connect across the supply chain so as to identify solutions, make the networks robust, and also explore certain new opportunities, hence reinforcing the role of API China as that of a trusted marketplace wherein business relationships take tangible shape.
One of the spokespersons for Reed Sinopharm Exhibitions remarked that API China has for long been the cornerstone of the pharmaceutical ecosystem in China. At this 93rd edition, they witnessed vibrant exchanges, partnerships, and also innovations all throughout excipients, APIs, packaging, biopharma as well as manufacturing technologies domains, thereby bringing to the fore the role that this show plays as a catalyst in terms of industry progress.
An Absolute Industry Landscape
It is worth noting that this edition of API China went beyond product showcases and put light on active engagement throughout the overall pharmaceutical value chain. Apparently, the four co-located segments went on to serve as dynamic hubs in terms of discovery and networking as well as collaboration, therefore creating an integrated environment wherein the suppliers and buyers could delve deep into the full journey – right from molecule to medicine. Together, they reinforced the reputation of API China as the most comprehensive platform in the industry when it comes to connections and growth.
The President of Hualian Pharmaceutical Machinery, Yuan Xiaolei, said that API China still remains a significant platform as far as long-standing exhibitors like his company are concerned. He added that they have been participating in API China ever since 2007, and every edition offers an invaluable opportunity so as to reconnect with the longtime partners and also meet new contacts. Due to its broad showcase of APIs and along with it packaging solutions, the event goes on to be an excellent venue when it comes to sourcing as well as building some very meaningful business relationships.
The Sales Director of Sichuan Dingke Pharmaceuticals, Maggie Liu, described her company’s debut in API China as a very productive and, of course, insightful experience. She said that as a first-time participant, API China has indeed been an eye-opening experience for them and that they have connected with numerous potential customers and also gathered valuable market data and insights, which are going to guide their next steps.
When we talk of an international buyer’s viewpoint, Marketing Manager of Helixon Labs from Pakistan, Squib Waheed, said that the event offered pretty strong opportunities in order to expand cross-border collaboration. He further said that he came to API China to look out for sourcing opportunities for their pharmaceutical and clinical manufacturing requirements, and the experience of the event has indeed exceeded his expectations, as he has met numerous capable suppliers and also identified many promising products for certain upcoming projects, therefore laying the foundation for consistent collaborations with industry players from China.
Apart from the exhibition floor, API China’s 93rd edition went on to feature a very comprehensive line-up of concurrent forums as well as technical conferences that addressed certain key priorities throughout the pharmaceutical value chain of China. Topics went on to span regulatory updates, green development, manufacturing excellence, and also emerging therapeutic frontiers, hence reflecting the focus on quality, innovation as well as sustainable growth of the industry.
Highlights of this pharmaceutical ingredients exhibition in China were in-depth discussions pertaining to generic drug manufacturing efficiency, lipid-based drug delivery, pharmaceutical excipient GMP compliance, and also traditional Chinese medicine – TCM quality advancement along with green transformation in pharmaceutical engineering. Notably, the event also hosted the 40th China Pharmaceutical Industry Market Information Conference, which brought together policymakers along with industry leaders to share their respective data-driven insights related to market trends and also policy direction.
Interestingly, the new thematic sessions explored nutritional health opportunities when it comes to pharma enterprises, innovation in terms of the pet medicine supply chain, and also technological progress in chemical as well as process safety, in addition to certain forward-looking exchanges when it comes to pharma export strategies, eCTD execution, and also intelligent process design.
All put together, these sessions reinforced the role of API China as a prominent platform for knowledge sharing as well as cross-disciplinary collaboration, therefore driving the consistent advancement of the pharmaceutical and biopharmaceutical sectors from China.
According to the Chairperson of IPEC China, Ms. Cloris Tian, partnering with API China enables them to engage the much broader pharmaceutical ecosystem in a meaningful dialogue. It creates a valuable opportunity when it comes to local as well as global excipient experts, users, manufacturers, and also other stakeholders to go ahead and exchange insights related to the latest regulatory developments that are taking place in China and also across the world, align on quality anticipations and best practices, and also make the collaborations across markets more robust. By way of curating content around the sector’s most pressing requirements, they aim to advance their shared objectives of making sure of the quality and safety of pharmaceutical excipients across the world.
Making the Global Collaboration Robust
Delegations and visitors from over 20 countries and regions participated in the event due to its growing international relevance that led to exploring collaboration opportunities. Discussions with regard to cross-border cooperation, quality management as well as technology transfer went on to underscore the continued importance of API China as a bridge between the domestic industry and the worldwide pharmaceutical community.
What’s Next?
Apparently, the 94ᵗʰ installment of API China is going to return to Shanghai from 13 to 15 May 2026, hence continuing with its mission to connect technologies, ideas, and partnerships that drive pharmaceutical progress. With over 90 successful editions to date, API China is indeed the proven platform wherein business opportunities in the pharmaceutical industry in China take shape.
